Company Overview and News

 
Velpic shareholders approve sale of Velpic business and change of company name

2018-09-21 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) shareholders have approved for the sale of its Velpic business to Damstra Technology Pty Ltd as well as a change in name to VPCL Limited.
VPC

 
Velpic granted trading halt pending results of shareholder meeting

2018-09-20 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has been granted a trading halt by the ASX pending the results of an extraordinary general meeting of shareholders today.
VPC

 
Velpic substantial holder Merchant Opportunities Fund lifts stake

2018-08-09 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) substantial shareholder, Merchant Opportunities Fund, has lifted its stake in the company through on-market purchases.
VPC

 
Velpic secures better offer for the sale of its customer book and intellectual property

2018-08-07 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has received an offer from Damstra Technology Pty Ltd to purchase its customer contracts that is superior to the deal agreed with Go1 Pty Ltd, revealed on July 13, 2018.
VPC

 
Velpic to sell Dash Digital business for $50,000

2018-08-06 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has entered into an agreement to sell its Dash Digital customer contracts for $50,000 to Choose Digital Pty Ltd.
VPC

 
Velpic enters trading halt following third party interest to acquire its businesses

2018-07-24 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has been granted a trading halt by the ASX after receiving unsolicited interest from third parties to acquire either the Velpic or the Dash Digital businesses.
VPC

 
Velpic enters trading halt ahead of news release

2018-07-20 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has been granted a trading halt by the ASX pending the release of an update on the proposed disposal of part of the company’s business which will require the approval of shareholders.
VPC

 
Velpic disposes of e-learning business for estimated $2.4 million

2018-07-13 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has agreed to sell the customer book of its learning management system (LMS) business to an existing partner, GO1 Pty Ltd.
VPC

 
Velpic prepares to dispose part of its business

2018-07-10 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has been granted a trading halt by the ASX pending the release of information regarding a proposed disposal of part of the company’s business.
VPC

 
Velpic has strongest quarter of revenue growth yet

2018-04-08 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has had a strong quarter of revenue growth across its learning management system (LMS).
VPC

 
Velpic appoints globally experienced Justin Klintberg to board to assist in next growth phase

2018-04-02 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has appointed Justin Klintberg to the board of directors following the resignations of Harry Karelis and Daniel Rohr.
VPC

35
Velpic and NowForce collaborate to address global security issues

2018-03-22 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) was active on all fronts in 2017, and there is early evidence in 2018 that the initiatives undertaken by the group are starting to pay dividends.
GJV VPC AAI NWS NWSA COF MALRY MALRF MIN AA

 
Velpic secures first client from NowForce partnership in ASX-listed Threat Protect

2018-03-21 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has secured its first client under its reseller agreement related to the NowForce platform in Threat Protect (ASX:TPS).
TPS VPC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:VPC / VELPIC LIMITED on message board site Silicon Investor.

Valkyries Petroleum (VPC) Valkyries Petroleum (VPC) Valkyries Petroleum (VPC)